card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

In vitro suppressive Treg bioassays for screening of candidate therapeutics

Home / Insights / In vitro suppressive Treg bioassays for screening of candidate therapeutics

The increasing interest in the tumor microenvironment leads to a focus on new bioassays to represent all the players of the cancer immune response. Some of these players like regulatory T cells play an important role by downregulating the anti-tumor response. Their regulation mechanisms constitute an important target for new therapeutics. In order to study these mechanisms in a human model, suppressive Treg bioassays mimicking the suppressive action of these cells were developed and optimized. In vitro suppressive assays come with many technical challenges, therefore protocols for the purification and in vitro culture of regulatory T cells were optimized and fine-tuned to result in an optimal assay window e and allow screening of multiple candidates. Donor-to-donor variation is controlled by pre-evaluation of multiple donors and standardized methods are used for isolation and in vitro culture of responding and suppressive cells. Access to a large and broad panel of healthy donors is required for the evaluation of therapeutic agents targeting the regulatory T cell pathway.

 

Complete the form below to view and download our scientific poster.